HUP0203564A3 - Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them - Google Patents

Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them

Info

Publication number: HUP0203564A3
Authority: HU; Hungary
Prior art keywords: heteroalkylamino; inhibitors; preparation; pharmaceutical compositions; compositions containing
Prior art date: 1999-10-21

Application number

HU0203564A

Other languages

English (en)

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-21

Filing date

2000-10-13

Publication date

2004-07-28

2000-10-13 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2003-02-28 Publication of HUP0203564A2 publication Critical patent/HUP0203564A2/hu

2004-07-28 Publication of HUP0203564A3 publication Critical patent/HUP0203564A3/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Virology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)

HU0203564A 1999-10-21 2000-10-13 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them HUP0203564A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16080399P	1999-10-21	1999-10-21
US21374300P	2000-06-22	2000-06-22
PCT/EP2000/010088 WO2001029042A1 (en)	1999-10-21	2000-10-13	Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase

Publications (2)

Publication Number	Publication Date
HUP0203564A2 HUP0203564A2 (hu)	2003-02-28
HUP0203564A3 true HUP0203564A3 (en)	2004-07-28

Family

ID=26857240

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0203564A HUP0203564A3 (en)	1999-10-21	2000-10-13	Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them

Country Status (27)

Country	Link
US (1)	US6451804B1 (hu)
EP (1)	EP1228070B1 (hu)
JP (1)	JP3961830B2 (hu)
KR (1)	KR100523120B1 (hu)
CN (1)	CN1171889C (hu)
AR (1)	AR026084A1 (hu)
AT (1)	ATE353329T1 (hu)
AU (1)	AU776250B2 (hu)
BR (1)	BR0015243A (hu)
CA (1)	CA2388142C (hu)
CZ (1)	CZ20021744A3 (hu)
DE (1)	DE60033307T2 (hu)
ES (1)	ES2280247T3 (hu)
HK (1)	HK1051039A1 (hu)
HR (1)	HRP20020328A2 (hu)
HU (1)	HUP0203564A3 (hu)
IL (1)	IL149100A0 (hu)
MA (1)	MA26837A1 (hu)
MX (1)	MXPA02003950A (hu)
NO (1)	NO20021781L (hu)
NZ (1)	NZ518119A (hu)
PE (1)	PE20010758A1 (hu)
PL (1)	PL357502A1 (hu)
RU (1)	RU2265606C2 (hu)
TR (1)	TR200201057T2 (hu)
WO (1)	WO2001029042A1 (hu)
YU (1)	YU29102A (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR200003429T2 (tr)	1998-05-26	2001-07-23	Warner-Lambert Company	Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
PL374544A1 (en) *	2002-04-03	2005-10-31	F.Hoffmann-La Roche Ag	Imidazo fused compounds
AU2003225072A1 (en) *	2002-04-19	2003-11-03	Smithkline Beecham Corporation	Novel compounds
CA2492033A1 (en)	2002-07-09	2004-01-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US7196090B2 (en)	2002-07-25	2007-03-27	Warner-Lambert Company	Kinase inhibitors
ATE374201T1 (de) *	2002-08-06	2007-10-15	Hoffmann La Roche	6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
US7084270B2 (en) *	2002-08-14	2006-08-01	Hoffman-La Roche Inc.	Pyrimido compounds having antiproliferative activity
TW200413381A (en)	2002-11-04	2004-08-01	Hoffmann La Roche	Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7112676B2 (en)	2002-11-04	2006-09-26	Hoffmann-La Roche Inc.	Pyrimido compounds having antiproliferative activity
JP2006514624A (ja) *	2002-11-18	2006-05-11	エフ．ホフマン−ラ　ロシュ　アーゲー	ジアジノピリミジン類
KR20050111636A (ko)	2003-04-10	2005-11-25	에프. 호프만-라 로슈 아게	피리미도 화합물
BRPI0413005A (pt) *	2003-07-29	2006-09-26	Irm Llc	compostos e composições como inibidores da proteìna cinase
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP2008509964A (ja)	2004-08-31	2008-04-03	エフ．ホフマン−ラロシュアーゲー	７−アミノ−３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及びプロテインキナーゼ阻害剤としての使用
BRPI0514738A (pt)	2004-08-31	2008-06-24	Hoffmann La Roche	derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
WO2006038112A1 (en) *	2004-10-01	2006-04-13	Warner-Lambert Company Llc	Use of kinase inhibitors to promote neochondrogenesis
US20090131430A1 (en) *	2004-11-23	2009-05-21	Palle Venkata P	Pyrido'2,3-dipyrimidines as anti-inflammatory agents
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006082492A1 (en) *	2005-02-02	2006-08-10	Ranbaxy Laboratories Limited	Azabicyclo derivatives as anti-inflammatory agents
WO2007074047A1 (de) *	2005-12-22	2007-07-05	Basf Se	Verfahren zur herstellung von zyklischen o-alkylierten aminoalkoholen
WO2007088014A1 (en)	2006-01-31	2007-08-09	F. Hoffmann-La Roche Ag	7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
ES2301380B1 (es)	2006-08-09	2009-06-08	Laboratorios Almirall S.A.	Nuevos derivados de 1,7-naftiridina.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es)	2007-04-26	2010-09-23	Laboratorios Almirall S.A.	Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
GB2452696B (en) *	2007-08-02	2009-09-23	Cambridge Entpr Ltd	3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
EP2108641A1 (en)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
WO2011040509A1 (ja)	2009-09-30	2011-04-07	東レ株式会社	２，３－ジヒドロ－１ｈ－インデン－２－イルウレア誘導体及びその医薬用途
EP2322176A1 (en)	2009-11-11	2011-05-18	Almirall, S.A.	New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
WO2011065800A2 (ko) *	2009-11-30	2011-06-03	주식회사 오스코텍	피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN102816162B (zh) *	2011-06-10	2016-04-27	中国科学院广州生物医药与健康研究院	嘧啶并嘧啶酮类化合物及其药用组合物和应用
US9611267B2 (en)	2012-06-13	2017-04-04	Incyte Holdings Corporation	Substituted tricyclic compounds as FGFR inhibitors
JP6104377B2 (ja) *	2012-07-11	2017-03-29	ブループリントメディシンズコーポレイション	線維芽細胞成長因子受容体の阻害剤
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
CN105307657B (zh) *	2013-03-15	2020-07-10	西建卡尔有限责任公司	杂芳基化合物和其用途
CA2907243C (en)	2013-03-15	2021-12-28	Celgene Avilomics Research, Inc.	Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
US9321786B2 (en)	2013-03-15	2016-04-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
EP2986610B9 (en)	2013-04-19	2018-10-17	Incyte Holdings Corporation	Bicyclic heterocycles as fgfr inhibitors
DK3395814T3 (da)	2013-10-25	2022-07-04	Blueprint Medicines Corp	Hæmmere af fibroblastvækstfaktorreceptoren
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2895769T3 (es)	2015-02-20	2022-02-22	Incyte Corp	Heterociclos bicíclicos como inhibidores de FGFR
WO2017031116A1 (en) *	2015-08-18	2017-02-23	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Small molecule inhibitors of ku70/80 and uses thereof
WO2018004258A1 (ko) *	2016-06-28	2018-01-04	한미약품 주식회사	신규한 헤테로시클릭 유도체 화합물 및 이의 용도
KR20180002053A (ko)	2016-06-28	2018-01-05	한미약품 주식회사	신규한 헤테로시클릭 유도체 화합물 및 이의 용도
WO2018053373A1 (en)	2016-09-16	2018-03-22	The General Hospital Corporation	Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
US11285158B2 (en)	2017-02-28	2022-03-29	The General Hospital Corporation	Uses of pyrimidopyrimidinones as SIK inhibitors
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AU2018346709A1 (en)	2017-10-05	2020-04-16	Fulcrum Therapeutics, Inc.	Use of p38 inhibitors to reduce expression of DUX4
US11466004B2 (en)	2018-05-04	2022-10-11	Incyte Corporation	Solid forms of an FGFR inhibitor and processes for preparing the same
CN112566912A (zh)	2018-05-04	2021-03-26	因赛特公司	Fgfr抑制剂的盐
EA202191800A1 (ru) *	2018-12-27	2021-09-13	Ле Лаборатуар Сервье Сас	Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (ja)	2019-10-14	2022-12-15	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) *	2019-10-31	2019-12-18	Cancer Research Tech Ltd	Compounds, compositions and therapeutic uses thereof
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
WO2021113479A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8814352D0 (en)	1988-06-16	1988-07-20	Smith Kline French Lab	Chemical compounds
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6147080A (en) *	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
EP1025102B1 (en) *	1997-10-20	2004-05-19	F. Hoffmann-La Roche Ag	Bicyclic kinase inhibitors
TR200003429T2 (tr) *	1998-05-26	2001-07-23	Warner-Lambert Company	Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
DE69920732T2 (de) *	1998-10-23	2006-02-23	F. Hoffmann-La Roche Ag	Bicyclische stickstoffheteroaryl verbindungen

2000
- 2000-10-13 AT AT00967864T patent/ATE353329T1/de not_active IP Right Cessation
- 2000-10-13 WO PCT/EP2000/010088 patent/WO2001029042A1/en active Search and Examination
- 2000-10-13 HU HU0203564A patent/HUP0203564A3/hu unknown
- 2000-10-13 MX MXPA02003950A patent/MXPA02003950A/es active IP Right Grant
- 2000-10-13 BR BR0015243-9A patent/BR0015243A/pt not_active IP Right Cessation
- 2000-10-13 IL IL14910000A patent/IL149100A0/xx unknown
- 2000-10-13 TR TR2002/01057T patent/TR200201057T2/xx unknown
- 2000-10-13 PL PL00357502A patent/PL357502A1/xx not_active Application Discontinuation
- 2000-10-13 NZ NZ518119A patent/NZ518119A/en unknown
- 2000-10-13 EP EP00967864A patent/EP1228070B1/en not_active Expired - Lifetime
- 2000-10-13 AU AU77873/00A patent/AU776250B2/en not_active Ceased
- 2000-10-13 ES ES00967864T patent/ES2280247T3/es not_active Expired - Lifetime
- 2000-10-13 JP JP2001531840A patent/JP3961830B2/ja not_active Expired - Fee Related
- 2000-10-13 CA CA002388142A patent/CA2388142C/en not_active Expired - Fee Related
- 2000-10-13 CZ CZ20021744A patent/CZ20021744A3/cs unknown
- 2000-10-13 RU RU2002112753/04A patent/RU2265606C2/ru not_active IP Right Cessation
- 2000-10-13 KR KR10-2002-7005031A patent/KR100523120B1/ko not_active IP Right Cessation
- 2000-10-13 CN CNB008146624A patent/CN1171889C/zh not_active Expired - Fee Related
- 2000-10-13 DE DE60033307T patent/DE60033307T2/de not_active Expired - Fee Related
- 2000-10-13 YU YU29102A patent/YU29102A/sh unknown
- 2000-10-17 PE PE2000001104A patent/PE20010758A1/es not_active Application Discontinuation
- 2000-10-19 AR ARP000105489A patent/AR026084A1/es not_active Application Discontinuation
- 2000-10-20 US US09/693,337 patent/US6451804B1/en not_active Expired - Fee Related
2002
- 2002-04-12 HR HR20020328A patent/HRP20020328A2/hr not_active Application Discontinuation
- 2002-04-16 NO NO20021781A patent/NO20021781L/no not_active Application Discontinuation
- 2002-04-19 MA MA26612A patent/MA26837A1/fr unknown
2003
- 2003-05-06 HK HK03103208A patent/HK1051039A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ20021744A3 (cs)	2002-08-14
CN1171889C (zh)	2004-10-20
YU29102A (sh)	2004-12-31
CA2388142C (en)	2008-12-09
RU2002112753A (ru)	2004-01-20
BR0015243A (pt)	2002-07-16
ES2280247T3 (es)	2007-09-16
MA26837A1 (fr)	2004-12-20
MXPA02003950A (es)	2002-10-23
AR026084A1 (es)	2002-12-26
AU776250B2 (en)	2004-09-02
HUP0203564A2 (hu)	2003-02-28
WO2001029042A1 (en)	2001-04-26
DE60033307T2 (de)	2007-07-12
NZ518119A (en)	2004-02-27
EP1228070A1 (en)	2002-08-07
CN1382144A (zh)	2002-11-27
TR200201057T2 (tr)	2002-09-23
HRP20020328A2 (en)	2004-02-29
AU7787300A (en)	2001-04-30
RU2265606C2 (ru)	2005-12-10
ATE353329T1 (de)	2007-02-15
KR20020038963A (ko)	2002-05-24
CA2388142A1 (en)	2001-04-26
KR100523120B1 (ko)	2005-10-20
JP2003512378A (ja)	2003-04-02
DE60033307D1 (en)	2007-03-22
IL149100A0 (en)	2002-11-10
JP3961830B2 (ja)	2007-08-22
NO20021781D0 (no)	2002-04-16
PE20010758A1 (es)	2001-07-21
EP1228070B1 (en)	2007-02-07
US6451804B1 (en)	2002-09-17
PL357502A1 (en)	2004-07-26
NO20021781L (no)	2002-04-18
HK1051039A1 (en)	2003-07-18

Publication	Publication Date	Title
HUP0203564A3 (en)	2004-07-28	Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinease, process for their preparation and pharmaceutical compositions containing them
HUP0203477A3 (en)	2004-12-28	Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase, pharmaceutical compositions containing them and their preparations
HUP0203453A3 (en)	2003-07-28	Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0105174A3 (en)	2002-06-28	Heterocyclic inhibitors of p38, process for their preparation and medicaments containing them
IL130349A0 (en)	2000-06-01	Substituted nitrogen containing heterocycles as inhibitors of P38 protein pinase and pharmaceutical compositions containing the same
PL350522A1 (en)	2002-12-16	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
HUP0003690A3 (en)	2003-08-28	Polymeric derivatives of camptothecins, process for their preparation and pharmaceutical compositions containing them
HUP0401537A3 (en)	2005-06-28	Thiohydantoins, process for their preparation, pharmaceutical compositions containing them and use thereof for preparation of pharmaceutical compositions
HUP0201261A2 (en)	2002-08-28	Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them
HUP0203052A3 (en)	2004-06-28	Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203122A3 (en)	2004-01-28	Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0300782A3 (en)	2003-11-28	Nitrogen-containing heterocyclic caspase inhibitors process for their preparation, pharmaceutical compositions containing them and use thereof
HUP0203142A3 (en)	2003-03-28	Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0104204A3 (en)	2002-06-28	Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof
HUP0301117A3 (en)	2004-01-28	Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0103633A2 (hu)	2002-02-28	Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények
HUP0203183A3 (en)	2006-02-28	Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use
HUP0202897A3 (en)	2004-12-28	Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them
HUP0200881A2 (en)	2002-08-28	Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0203140A3 (en)	2004-06-28	Bicyclic imidazo-5-yl-amine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0401292A3 (en)	2011-01-28	Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
IL167907A (en)	2010-12-30	Bicyclic inhibitors of hormone sensitive lipase, process for their preparation and pharmaceutical compositions comprising them
HUP0203422A3 (en)	2004-12-28	Imidazole derivatives as phosphodiesterase vii inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0200816A3 (en)	2003-06-30	Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases, process for their preparation and pharmaceutical compositions containing them
HUP0201730A2 (en)	2002-09-28	Thienopyrimidines as phosphodiesterase inhibitors, their use, pharmaceutical compositions containing them and process for the preparation thereof